. Author manuscript; available in PMC: 2024 Jan 1.

Published in final edited form as: Gynecol Oncol. 2022 Nov 17;168:68–75. doi: 10.1016/j.ygyno.2022.10.018

Table 1:

Characteristics of studies included in the analysis

Study abbreviation	Study full name	Study location	Year of diagnosis	Total of participants included in the main analysis	Diagnosed before 2007 N=1,359 (66.2%)		Diagnosed in 2007 or later N=695 (33.8%)
Study abbreviation	Study full name	Study location	Year of diagnosis	Total of participants included in the main analysis	Macrosco pic residual disease n (%)	No macroscopic residual disease n (%)	Macroscopic residual disease n (%)	No macroscopic residual disease n (%)

AUS²⁹	Australian Ovarian Cancer Study	Australia	2001-2006	544	424 (77.9%)	120 (22.1%)	0	0
OPL³⁰	Ovarian Cancer Prognosis and Lifestyle Study	Australia	2012-2015	245	0	0	148 (60.4%)	97 (39.6%)
HAW³¹	Hawaii Ovarian Cancer Case-Control Study	Hawai’i, US	1994-2006	65	47 (72.3%)	18 (27.7%)	0	0
HOP³²	Hormones and Ovarian Cancer Prediction	Western Pennsylvani a, Northeast Ohio, Western New York, US	2003-2008	289	148 (76.7%)	45 (23.3%)	64 (66.7%)	32 (33.3%)
LAX	Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute	California, US	1986-2008	134	51 (45.9%)	60 (54.1%)	13 (56.5%)	10 (43.5%)
MAYO^{33, 34}	Mayo Clinic Ovarian Cancer Study	Minnesota, US	1993-2014	569	177 (70.0%)	76 (30.0%)	144 (45.6%)	172 (54.4%)
NEC³⁵	New England Case Control Study	New Hampshire and Eastern Massachuse tts, US	1992-2008	208	141 (73.1%)	52 (26.9%)	11 (73.3%)	4 (26.7%)

				2,054	988 (72.7%)	371 (27.3%)	380 (54.7%)	315 (45.3%)